CRP and neoplasm: Various factors associated with NTX have been proposed in other series2–4,11,16, some being related to the patient’s history (high pre-treatment tumour burden, low baseline platelet count, high baseline CRP), and others to the way the patient is responding to treatment (occurrence of CRS, CAR T-cell expansion, fever on day 3).